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Uric acid is a danger signal contributing to inflammation. Its relevanceto allogeneic stem cell transplantation (alloSCT) derives from preclin-ical models where the depletion of uric acid led to improved survival
and reduced graft-versus-host disease (GvHD). In a clinical pilot trial, peri-
transplant uric acid depletion reduced acute GvHD incidence.  This prospec-
tive international multicenter study aimed to investigate the association of
uric acid serum levels before start of conditioning with alloSCT outcome.
We included patients with acute leukemia, lymphoma or myelodysplastic
syndrome receiving a first matched sibling alloSCT from peripheral blood,
regardless of conditioning. We compared outcomes between patients with
high and low uric acid levels with univariate- and multivariate analysis using
a cause-specific Cox model. Twenty centers from 10 countries reported data
on 366 alloSCT recipients. There were no significant differences in terms of
baseline co-morbidity and disease stage between the high- and low uric acid
group. Patients with uric acid levels above median measured before start of
conditioning did not significantly differ from the remaining in terms of acute
GvHD grades II-IV incidence (Hazard ratio [HR] 1.5, 95% Confidence inter-
val [CI]: 1.0-2.4, P=0.08). However, they had significantly shorter overall sur-
vival (HR 2.8, 95% CI: 1.7-4.7, P<0.0001) and progression free survival (HR
1.6, 95% CI: 1.1-2.4, P=0.025). Non-relapse mortality was significantly
increased in alloSCT recipients with high uric acid levels (HR 2.7, 95% CI:
1.4-5.0, P=0.003). Finally, the incidence of relapse after alloSCT was
increased in patients with higher uric acid levels (HR 1.6, 95% CI: 1.0-2.5,
P=0.04). We conclude that high uric acid levels before the start of condition-
ing correlate with increased mortality after alloSCT.
Association of uric acid levels before start of
conditioning with mortality after allogeneic
hematopoietic stem cell transplantation – a
prospective, non-interventional study of the
EBMT Transplant Complication Working Party
Olaf Penack,1  Christophe Peczynski,2 Steffie van der Werf,3 Jürgen Finke,4
Arnold Ganser,5 Helene Schoemans,6 Jiri Pavlu,7 Riitta Niittyvuopio,8 
Wilfried Schroyens,9 Leylagül Kaynar,10 Igor W. Blau,1 Walter van der Velden,11
Jorge Sierra,12 Agostino Cortelezzi,13 Gerald Wulf,14 Pascal Turlure,15 
Montserat Rovira,16 Zubeydenur Ozkurt,17 Maria J. Pascual-Cascon,18 
Maria C. Moreira,19 Johannes Clausen,20 Hildegard Greinix,21
Rafael F. Duarte22# and Grzegorz W. Basak23#
1Charité Universitätsmedizin Berlin, Berlin, Germany; 2EBMT Statistical Unit, Paris,
France; 3EBMT Data Office, Leiden, the Netherlands; 4University of Freiburg, Freiburg,
Germany; 5Hannover Medical School, Hannover, Germany; 6Department of Hematology,
University Hospital Leuven and KU Leuven, Leuven, Belgium; 7Imperial College, London,
UK; 8HUCH Comprehensive Cancer Center, Helsinki, Finland; 9Antwerp University
Hospital, Antwerp, Belgium; 10Erciyes University Medical Faculty, Kayseri, Turkey;
11Radboud University – Nijmegen Medical Centre, Nijmegen, the Netherlands; 12Hospital
Santa Creu I Sant Pau, Barcelona, Spain; 13Fondazione IRCCS – Ca’Granda, Milan, Italy;
14Universitätsklinikum Göttingen, Göttingen, Germany; 15CHRU Limoges, Limoges,
France; 16Hospital Clinic, Barcelona, Spain; 17Gazi University Faculty of Medicine, Ankara,
Turkey; 18Hospital Regional de Málaga, Malaga, Spain; 19Instituto National do Cancer,
Rio de Janeiro, Brazil; 20Elisabethinen-Hospital, Linz, Austria; 21LKH – University Hospital
Graz, Graz, Austria; 22Hospital Universitario Puerta de Hierro, Madrid, Spain and
23Medical University of Warsaw, Warsaw, Poland 
#RFD and GWB contributed equally as co-senior authors.
ABSTRACT
Introduction
High treatment-associated complication rates remain an
important challenge to the success of allogeneic
hematopoietic stem cell transplantation (alloSCT). A com-
mon mechanism of the major infectious- and non-infec-
tious complications after alloSCT, such as graft-versus-host
disease (GvHD) and sepsis, is severe inflammation.
Critical to excess inflammation after alloSCT are host bio-
molecules termed ‘endogenous danger signals’, which can
initiate and maintain non-infectious inflammatory
responses by acting as pro-inflammatory mediators.1,2 One
such molecule is uric acid. During conditioning for
alloSCT, uric acid is released from injured cells and
reduced renal clearance may contribute to high uric acid
serum levels.3,4 Uric acid acts as a danger signal by enhanc-
ing T-cell responses via activation of the NOD-like recep-
tor protein (NLRP) 3 inflammasome.5,6 A pre-clinical study
has provided basic evidence on the regulation of GvHD by
uric acid via Nlrp3 inflammasome–mediated IL-1 produc-
tion.7 The significance of uric acid for alloSCT outcome
has been underlined by results from a pilot study reporting
reduced incidence of acute GvHD in patients undergoing
alloSCT after depletion of uric acid using urate oxidase.8
Based on these results, and because uric acid is a routine
laboratory parameter assessed in patients undergoing
alloSCT, there is a strong rationale to investigate the use
of uric acid as a biomarker and possibly as a therapeutic
target during alloSCT. To study the role of uric acid levels
in alloSCT, the Transplant Complications Working Party
(TCWP) of the European Society for Blood and Marrow
Transplantation (EBMT) performed a prospective, multi-
center, non-interventional study. We hypothesized that a
high uric acid level prior to alloSCT is an independent risk
factor for increased mortality and for the development of
severe acute GvHD.  
Methods
Data source, study design and data collection
We asked EBMT centers performing more than 50 alloSCT per
year if they were willing to participate in this prospective study.
Twenty centers in ten countries agreed to participate. Data collec-
tion for the EBMT registry was approved by the institutional
review board and/or Ethics Committee in all centers. Data were
prospectively collected between  August, 2014 and February,
2018. Consecutive alloSCT recipients with acute leukemia, lym-
phoma or myelodysplastic syndrome (MDS) receiving a first
matched sibling alloSCT from peripheral blood, regardless of con-
ditioning, were eligible, provided they had signed an informed
consent document that permitted sharing of clinical data accord-
ing to national rules. Basic data on patient and disease characteris-
tics as well as longer term follow-up was taken from minimal
essential data (MED-A) forms, which are submitted from all con-
secutive patients to the central EBMT registry. In addition, we
designed registration and MED-B/C forms that were prospectively
collected and specific to this study (see the Online Supplementary
Materials and Methods). The MED-B/C form contained detailed
information on uric acid serum levels prior to alloSCT, patient
characteristics, infectious- as well as non-infectious complications,
GvHD staging, morbidity and mortality. Uric acid levels were
determined at the time of hospital admission for alloSCT directly
before the start of conditioning therapy. Treatment teams com-
pleted the specific forms at the time of registration and at day
+100 after alloSCT. 
Endpoints and statistical analyses
Patient, disease, and transplant-related characteristics for the
two cohorts (uric acid levels prior to alloSCT above median / uric
acid levels below median) were compared by using 2 statistics for
categorical variables and the Mann-Whitney test for continuous
variables. The primary endpoint was the incidence of acute
GvHD. Secondary endpoints were relapse incidence (RI), non-
relapse mortality (NRM), overall survival (OS), progression free
survival (PFS) and the incidence of chronic GvHD. PFS was
defined as survival with no evidence of relapse or progression. RI
was defined as the probability of having had a relapse during fol-
low-up time. Death without experiencing a relapse was a compet-
ing event. NRM was defined as death without evidence of relapse
or progression. OS was defined as the time from alloSCT to death,
regardless of the cause. Acute GvHD was graded according to the
modified Seattle-Glucksberg criteria9 and chronic GvHD accord-
ing to the revised Seattle criteria.10 Cumulative incidence was used
to estimate the endpoints of NRM, RI, acute and chronic GvHD to
accommodate for competing risks. To study acute and chronic
GvHD, we considered relapse and death to be competing events.
Probabilities of OS and PFS were calculated using the Kaplan–
Meier method. Univariate analyses were done using the Gray test
for cumulative incidence functions and the log rank test for OS
and PFS. A Cox proportional hazards model was used for multi-
variate regression. All variables differing significantly between the
two groups or factors associated with one outcome in univariate
analysis were included in the Cox model. The following variables
entered the multivariate models as possible confounders: age, sex
mismatch between recipient and donor, diagnosis, disease status,
Karnofsky score, number of CD34 cells given, intensity of condi-
tioning (EBMT definition: myeloablative conditioning (MAC) was
defined as total body irradiation (TBI) >6 Grey or oral busulfan >8
mg/kg or intravenous busulfan >6.4 mg/kg), type of GvHD pro-
phylaxis, ATG use, time from diagnosis to transplant, year of
transplant and CMV status. As the number of variables was too
high regarding the number of events, a stepwise selection using
Akaike information criterion (AIC)  was run for all the confound-
ing factors. The difference between the two cohorts was then
assessed in the final selected model.
Results were expressed as the hazard ratio (HR) with the 95%
confidence interval (95% CI). Proportional hazards assumptions
were checked systematically for all proposed models using the
Grambsch-Therneau residual-based test. All tests were two-sided.
The type I error rate was fixed at 0.05 for the determination of fac-
tors associated with time-to-event outcomes. Statistical analyses
were performed in November 2018 with R 3.4.2 (R Core Team
(2017). R: A language and environment for statistical computing. R
Foundation for Statistical Computing, Vienna, Austria. URL
https://www.R-project.org/.)
Results
Patients, transplant characteristics and uric acid
measurement
The entry criteria for analysis of primary and secondary
endpoints were fulfilled in 386 patients. We used the last
uric acid serum level that was masured in the individual
patients before start of conditioning. The median time
point of measurement was three days before start of con-
ditioning. The range was between 0 days (morning before
start of conditioning) to 22 days before conditioning. The
main patients and transplant characteristics that were
included in the analysis of OS are described in Table 1.
Most parameters were balanced between the two cohorts.
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Table 1. Patient characteristics.
                                                                        Uric acid ≤4.3 mg/dL (n=186)           Uric acid >4.3 mg/dL (n=180)                        P
Year of transplant median (range)[IQR]               2015 (2014-2018) [2015-2017]                  2015 (2014-2018) [2014-2016]                                0.10
Patient age (years) median(range)                                          52 (17-71)                                                      55 (20-71)                                                  0.11
Time from diagnosis to transplant                                              4 (1-61)                                                          5 (1-71)                                                    0.09
(months) median (range)                                                                     
Sex mismatch
Female to male                                                                              30 (17%)                                                        52 (29%)                                                   0.005
Other combination                                                                       148 (83%)                                                      125 (71%)
Missing                                                                                                    8                                                                       3                                                          
Diagnosis
Acute leukemia                                                                             130 (70%)                                                      118 (66%)                                                  0.7
Lymphoma                                                                                        17 (9%)                                                         19 (10%)
MDS                                                                                                  39 (21%)                                                        43 (24%)                                                   
Disease status
CR                                                                                                     120 (66%)                                                      125 (72%)                                                  0.2  
Not in CR                                                                                         61 (34%)                                                        48 (28%)
Missing                                                                                                    5                                                                       7                                                          
DRI                                                                                                                                                                                                                                                   0.7
Low                                                                                                    8 ( 4% )                                                          7 ( 4% )
Intermediate                                                                                107 ( 60% )                                                    105 ( 63% )
High                                                                                                 51 ( 30% )                                                      49 ( 30% )
Very high                                                                                          10 ( 6% )                                                          5 (3% )
Missing                                                                                                   10                                                                     14                                                         
ATG
No                                                                                                     100 (54%)                                                      106 (59%)                                                  0.3
Yes                                                                                                    86 (46%)                                                        74 (41%)                                                   
Conditioning intensity
MAC/Chemo                                                                                    46 (25%)                                                        37 (21%)                                                   0.2
MAC/TBI                                                                                           36 (20%)                                                        26 (15%)
RIC                                                                                                   102 (55%)                                                      115 (64%)                                                  
Missing                                                                                                    2                                                                       2                                                          
GvHD prophylaxis
Calcineurin inhibitor + MMF                                                     85 (48%)                                                        84 (47%)                                                   0.6
Calcineurin inhibitor + MTX                                                       64 (36%)                                                        71 (40%)
Calcineurin inhibitor mono                                                         27 (15%)                                                        22 (12%)
Missing                                                                                                   10                                                                      3                                                          
Donor/patient CMV                                                                                                                                                                                                                      0.2
-/-                                                                                                       28 (16%)                                                        38 (21%)                                                   
Other                                                                                               146 (83%)                                                      136 (78%)
Missing                                                                                                   12                                                                      6                                                          
Karnofsky score                                                                                                                                                                                                                           0.14
10-80                                                                                                 38 (21%)                                                        27 (15%)
90-100                                                                                              140 (78%)                                                      149 (84%)
Missing                                                                                                    8                                                                       4                                                          
HT-CI = 0                                                                                          64 ( 50% )                                                      56 ( 40% )                                                  0.19
HT-CI = 1 or 2                                                                                  20 ( 15% )                                                      32 ( 23% )
HT-CI ≥3                                                                                            45 ( 35% )                                                      51 ( 37% )
Missing                                                                                                     57                                                                     41                                                         
MDS: myelodysplastic syndrome; IQR: interquartile range; CR: complete remission; DRI: disease risk index; ATG: anti-thymocyte globulin; MAC: myeloablative conditioning; RIC:
reduced intensity conditioning; TBI: total body irradiation; GvHD: graft-versus-host disease; MMF: Mycophenolate mofetil; MTX: Methotrexate; CMV: cytomegalovirus; HT-CI:
hematopoietic cell transplantation cumulative incidence.
However, a higher percentage of sex mismatch transplants
in the direction of female donor to male recipient was
observed in the group of patients with uric acid above
median before alloSCT. The frequency of patients with
reduced-intensity conditioning (RIC) versus myeloablative
conditioning (MAC) did not differ significantly between
the high uric acid group and the low uric acid group
(P=0.077).  When looking exclusively at TBI (P=0.59) or by
mixing conditioning intensity and TBI (MAC/Chemo vs.
MAC/TBI vs. RIC: P=0.20), no statistically significant dif-
ference could be observed.
Incidence of acute and chronic GvHD 
In the present study, the incidence of acute GvHD
grades II-IV and grades III-IV in the whole population at
100 days were 25% and 11%, respectively. We observed
no significant differences in the frequency of clinically sig-
nificant acute GvHD grades II-IV in univariate (HR 1.2,
95% CI: 0.8-1.9, P=0.4) and multivariate (HR 1.5, 95%  CI:
1.0-2.4, P=0.08) analysis comparing the high- versus the
low uric acid cohorts. (Table 2 and Table 3). We found no
significant differences in the frequency of acute GvHD
grades III-IV in univariate (HR=1.8, 95% CI: 0.9-3.4,
P=0.08) and multivariate (HR 1.7, 95% CI: 0.9-3.2, P=0.11)
analysis in alloSCT recipients with uric acid levels above
cut-off before transplantation versus those with low uric
acid levels (Table 2 and Table 3). 
In the whole population, the incidence of chronic
GvHD at one year and two years was 27% and 40%,
respectively. The incidence of severe chronic GvHD at 1
year and 2 years was 18% and 24%, respectively. We
observed no differences in incidence and severity of
chronic GvHD between the two cohorts (Table 3 and
Table 4). The chronic GvHD incidence was significantly
lower in alloSCT recipients receiving anti-T-cell globulin
(ATG) as part of the conditioning regimen (ATG, HR 0.25
95% CI: 0.13-0.5, P<0.0001).
Survival endpoints
The median follow-up time was 15.2 months (95% CI:
13.1-17.0) and OS in the whole population at 1 year was
74%. We found, that OS and PFS of alloSCT recipients
with uric acid levels above cut-off, measured before start
of conditioning, were significantly shorter compared with
the low uric acid cohort (Figure 1A, OS univariate HR 2.4,
95% CI: 1.6-3.7, P<0.001; multivariate HR 2.8, 95% CI:
1.7-4.7, P<0.0001) (Figure 1B, PFS univariate HR 2.0, 95%
CI: 1.1-3.7, P=0.02; multivariate HR 2.7, 95% CI: 1.4-5.0,
P=0.003). Non-relapse mortality was significantly
increased in alloSCT recipients with high uric acid levels
prior to start of conditioning (Figure 2A, univariate HR 2.0,
95% CI: 1.1-3.7, P=0.02; multivariate HR 2.7, 95% CI: 1.4-
5.0, P=0.003). Multivariate as well as univariate analyses
are shown in Table 3 and Table 4. We conclude that serum
uric acid levels prior to alloSCT are an independent risk
factor for mortality.
At the last follow-up 29.3% of the patients were dead
(49.6% from relapse, 45.2% alloSCT-related causes and
2.6% from other causes). The causes of death in patients
without relapse were mainly due to infection. A descrip-
tive analysis of the causes of death is given in Table 5. 
Incidence of infections
We first looked at the incidence of infections in both
cohorts and found no significant differences (multivariate
HR 0.8, 95% CI: 0.6-1.1, P=0.4). We than looked at infec-
tion-related mortality and found a significant higher num-
ber of infection-related deaths in the high uric acid group
(Figure 2C, multivariate HR 2.6, 95% CI: 1.2-5.2, P=0.01).
Incidence of relapse
Since uric acid is known to be released from malignant
O. Penack et al.
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Table 2. Univariate global comparison of acute graft-versus-host dis-
ease shown at day +100 after allogeneic stem cell transplantation. 
Group                                              Acute GvHD              Acute GvHD
                                                     II-IV (95% CI)           III-IV (95% CI)
Uric acid </=4.3 mg/dL                        22% (17-29)                    8% (5-13)
Uric acid >4.3 mg/dL                             26% (20-33)                   14% (9-19)
P-value                                                             0.39                                 0.08
GvHD: graft-versus-host disease; CI: confidence interval.
Figure 1. Survival at one year after allogeneic stem cell transplantation. Overall survival (OS) (A) and progression free survival (PFS) (B) after allogeneic stem cell
transplantation (alloSCT) in cohorts according to uric acid serum levels prior to alloSCT: with high uric acid serum levels (blue line), patients with low uric acid levels
(red line). 
A B
Strata
O
S
P
FS
P
FSO
S
≤ 4.3 mg/dL
≤ 4.3 mg/dL
> 4.3 mg/dL
> 4.3 mg/dL
≤ 4.3 mg/dL
> 4.3 mg/dL
Strata
≤ 4.3 mg/dL
> 4.3 mg/dL
tumours, we were interested in a possible connection of
uric acid levels and disease relapse. We found that the
relapse incidence in all patients at 1 year was 13%. The
relapse incidence was moderately increased in the cohort
with higher uric acid levels (Figure 2B, Table 3 and Table
4, univariate HR 1.6, 95% CI: 1.0-2.5; P=0.09; multivariate
HR 1.6, 95% CI: 1.0-2.5, P=0.04). 
Discussion
This prospective study identifies uric acid levels, taken
before start of conditioning therapy, as a laboratory bio-
marker to predict mortality after alloSCT. 
In animal experiments and in a clinical pilot study the
depletion of uric acid with rasburicase led to a reduced fre-
quency of severe GvHD.7,8 Therefore, our initial hypothe-
sis was to primarily find an association between uric acid
with acute GvHD and then secondarily with NRM.
However, we found a strong positive association of uric
acid levels with mortality after alloSCT whereas the asso-
ciation between uric acid levels and acute GvHD inci-
dence was not statistically significant. One of the reasons
could be the low incidence of GvHD in our cohort due to
the patient characteristics of human leukocyte antigen
(HLA)-identical sibling transplant with a high proportion
of anti-thymocyte globulin (ATG) use. The use of in vivo
T-cell depletion with ATG in HLA-identical sibling
High uric acid levels and increased mortality after alloSCT
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Figure 2. Non-relapse mortality, relapse incidence and infection-related
mortality at one year after allogeneic stem cell transplantation.
Incidence of non-relapse mortality (NRM) (A), relapse incidence (RI) (B)
and infection-related mortality (C) after allogeneic stem cell transplanta-
tion (alloSCT) in cohorts according to uric acid serum levels prior to
alloSCT: patients with high uric acid serum levels (blue line), patients with
low uric acid levels (red line). 
A B
C
Table 3. Multivariate global comparison. 
Uric acid >4.3 mg/dL                                                           HR                                            95% CI                                                   P
versus ≤4,3 mg/dL                                                                
Overall Survival                                                                                     2,83                                                   1,72 - 4,68                                                       <0.0001
Progression Free Survival                                                                  1,59                                                   1,06 - 2,39                                                          0.03
Relapse Incidence                                                                               1,59                                                   1,02 - 2,49                                                          0.04
Non-Relapse Mortality                                                                        2,65                                                   1,41 - 5,01                                                         0.003
Chronic GvHD                                                                                        0,96                                                    0,63 -1,45                                                           0.84
Extensive Chronic GvHD                                                                    1,08                                                   0,62 - 1,88                                                          0.79
Acute GvHD II-IV                                                                                  1,52                                                   0,95 - 2,43                                                          0.08
Acute GvHD III-IV                                                                                 1,68                                                   0,88 - 3,19                                                          0.11
GvHD: graft-versus-host disease; HR: hazard ratio; CI: confidence interval.
≤ 4.3 mg/dL
> 4.3 mg/dL
≤ 4.3 mg/dL
> 4.3 mg/dL
≤ 4.3 mg/dL
> 4.3 mg/dL
alloSCT in European centres increased recently.11 This
trend is reflected by a higher frequency of ATG use in the
present study (41-46%) than we had initially expected.
Another likely reason is a hyperinflammatory status con-
nected to high uric acid levels not restricted to acute
GvHD with a negative impact on different relevant clini-
cal situations after alloSCT, such as sepsis12 and adult res-
piratory distress syndrome (ARDS).13 This view is sup-
ported by our observation that death due to both infec-
tious and non-infectious complications after alloSCT was
increased in patients with high uric acid levels.
Interestingly, an association of uric acid levels with
decreased solid organ transplant survival has been
described further underlining the significance of uric acid
for transplantation biology.14,15 Our study extends these
findings to the setting of alloSCT.
Our study contradicts results from a previous retrospec-
tive single centre study, which did not show any signifi-
cant association of uric acid levels prior to transplantation
to mortality after alloSCT.16 Differences in study designs
between the current larger, multicentre and prospective
study versus the already published smaller, single centre
and retrospective study may be the reason for the differ-
ing results.
A limitation of this clinical study is the lack of mecha-
nistic insight on the role of uric acid in development of
complications after alloSCT. The study design did not
allow the investigation of whether the impaired outcome
in the high urid acid cohort is due to an active role of uric
acid in causing inflammation or whether it is because uric
acid primarily is a surrogate biomarker reflecting a hyper-
inflammatory status and/or activity of the underlying
malignancy. However, we found no significant differences
regarding the disease status as well as disease risk index
(DRI) (complete remission [CR] vs. non-CR) in between
the two groups (high uric acid vs.low uric acid). In addition
there were no significant differences in the performance
status as well as the alloSCT-CI in between the two
groups. This data is no proof, but rather points in the
direction that high uric acid values were not merely a
reflection of advanced disease or increased co-morbidity
in our study.
A further limitation of our results is that our patient
population was restricted to alloSCT from HLA-identical
sibling donors. We are therefore unable to draw definite
conclusions from these results regarding the association of
uric acid levels with outcome in matched unrelated donor
alloSCT or in haploidentical alloSCT, which are increas-
ingly used. Another limitation is the incomplete under-
standing of the effects of uric acid on post alloSCT immu-
nity. While previous studies showed that uric acid leads to
a inflammatory status in leukocytes and our results
demonstrate impaired survival in alloSCT recipients with
uric acid levels above median, it may be premature to con-
clude that uric acid is a negative factor at any time around
alloSCT. There are clinical situations where immune acti-
vation is necessary and desired – e.g. in anti-infectious and
anti-tumor immunity. The impact of depleting uric acid on
immune activity in these situations remains to be deter-
mined. In addition, it is possible that uric acid is involved
in immune reconstitution as it has been suggested recently
that changes in uric acid serum levels can indicate incipi-
ent or remaining immunological activity after SCT or
induction therapy in patients with hematologic malignan-
cies.17
In conclusion, this study supports the use of serum uric
acid levels as biomarker for alloSCT outcome. 
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Table 4. Univariate global comparison of overall survival, non-relapse mortality, relapse incidence as well as chronic graft-versus-host disease
incidence and severity at one year after allogeneic stem cell transplantation.
Group                                                   OS                         PFS                           RI                     NRM                      cGvHD               Extensive cGvHD
                                                        (95% CI)                 (95% CI)                  (95% CI)             (95% CI)                  (95% CI)                    (95% CI)                                                               
Uric acid </=4.3 mg/dL                             81%                             71%                               19%                         10%                               28%                                 16% 
                                                                      (75-88)                        (64-79)                         (13-26)                    (6-16)                          (20-36)                           (10-24)
Uric acid                                                       66%                             56%                               27%                         17%                              26%                                 18% 
>4.3 mg/dL                                                (59-74)                        (48-64)                         (20-34)                   (12-24)                         (19-33)                           (12-25)
P-value                                                        <0.001                           0.001                               0.09                          0.02                                0.43                                  0.85
OS: overall survival; PFS: progression free survival;  NRM: non-relapse mortality; RI: relapse incidence: cGvHD: chronic graft-versus-host disease; CI: confidence intervall.
Table 5. Causes of death in both cohorts. 
                                                             Uric acid ≤4.3     Uric acid >4.3
                                                            (n=186) mg/dL    mg/dL (n=180)
Alive at last follow up                                      155 (83.3%)             106 (58.9%)
Dead                                                                     31 (16.7%)               74 (41.1%)
Dead due to relapse                                          13 (6.9%)                38 (21.1%)
Dead without relapse                                       18 (9.7%)                36 (20.0%)
Dead due to infection                                        5 (3.2%)                 20 (11.1%)
Dead due to GvHD                                              2 (1.0%)                  10 (5.6%)
Dead due to infection and GvHD                    3 (1.6%)                   5 (2.8%)
Dead due to other causes or unknown         8 (4.3%)                   1 (0.5%)
GvHD: graft-versus-host disease.                                                                     
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